ns 1619 has been researched along with Pulmonary Hypertension in 2 studies
NS 1619: structure given in first source
NS 1619 : A member of the class of benzimidazoles that is 1,3-dihydro-2H-benzimidazol-2-one in which the hydrogens at positions 1 and 5 are replaced are replaced by 2-hydroxy-5-(trifluoromethyl)phenyl and trifluoromethyl groups, respectively. It is an opener/activator of the large-conductance calcium-activated potassium channel (Bkca).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Revermann, M | 1 |
| Neofitidou, S | 1 |
| Kirschning, T | 1 |
| Schloss, M | 1 |
| Brandes, RP | 1 |
| Hofstetter, C | 1 |
| McCullough, DJ | 1 |
| Vang, A | 1 |
| Choudhary, G | 1 |
2 other studies available for ns 1619 and Pulmonary Hypertension
| Article | Year |
|---|---|
Inhalation of the BK(Ca)-opener NS1619 attenuates right ventricular pressure and improves oxygenation in the rat monocrotaline model of pulmonary hypertension.
Topics: Administration, Inhalation; Animals; Becaplermin; Benzimidazoles; Blotting, Western; Cell Proliferat | 2014 |
NS1619-induced vasodilation is enhanced and differentially mediated in chronically hypoxic lungs.
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Calcium Channels, L-Type; Chronic Disease; Disease | 2014 |